DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.

Cancer Letters
Xiangling ChenLiguang Lou

Abstract

Hsp90 regulates the stability of oncoproteins important in tumor development and progression, and represents a potential therapeutic target. However, all Hsp90 inhibitors currently in clinical trials target Hsp90 ATPase activity and exhibit low selectivity and high toxicity. In this study, we discovered a new Hsp90 inhibitor, DCZ3112, with a novel mechanism of action. DCZ3112 directly bound to the N-terminal domain of Hsp90 and inhibited Hsp90-Cdc37 interaction without inhibiting ATPase activity. DCZ3112 inhibited the proliferation predominantly in HER2-positive breast cancer cells, including those resistant to the classical Hsp90 inhibitor geldanamycin, which mainly targets ATPase. DCZ3112 produced synergistic in vitro activity in inhibiting cell proliferation, inducing G1-phase arrest and apoptosis, and reducing AKT and ERK phosphorylation. Consistent with this, DCZ3112 alone inhibited the growth of HER2-positive BT-474 xenografts, and exhibited enhanced antitumor activity when combined with the anti-HER2 antibody trastuzumab. Importantly, DCZ3112 also significantly inhibited the growth of trastuzumab-resistant BT-474 cells, and combined treatment retained synergistic antitumor activity. Thus, our findings show that disruptin...Continue Reading

References

Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Apr 5, 2003·Cancer Cell·Jennifer S IsaacsLen Neckers
Feb 6, 2004·Molecular & Cellular Proteomics : MCP·Jeffrey S RossGabriel N Hortobagyi
Nov 18, 2006·The Oncologist·Beverly Moy, Paul E Goss
Apr 6, 2007·Cancer Research·Elah PickHarriet M Kluger
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shanu ModiClifford A Hudis
Jan 19, 2008·Molecular Cancer Therapeutics·Tao ZhangDuxin Sun
Apr 24, 2008·Breast Cancer Research : BCR·Michael Rugaard JensenPatrick Chène
Jul 23, 2008·Current Opinion in Pharmacology·Tony TaldoneGabriela Chiosis
Sep 23, 2009·Biochemical Pharmacology·Yanke YuDuxin Sun
Dec 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paula R PohlmannRay Mernaugh
Nov 26, 2010·Expert Opinion on Drug Safety·Robyn J MacFarlane, Karen A Gelmon
Sep 29, 2011·Biochimica Et Biophysica Acta·Jing LiJohannes Buchner
Jan 10, 2012·Biochimica Et Biophysica Acta·Luke Whitesell, Nancy U Lin
Mar 9, 2012·Expert Opinion on Drug Discovery·Hardik J PatelTony Taldone
Mar 19, 2013·Nature Chemical Biology·Sigrun PolierLaurence H Pearl
Feb 21, 2014·Molecular Cancer Research : MCR·Jaime AcquavivaDavid A Proia
Mar 29, 2014·Expert Opinion on Investigational Drugs·Komal JhaveriGabriela Chiosis
Aug 8, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Zhanhui WangSamuel So
Feb 19, 2015·The New England Journal of Medicine·Sandra M SwainUNKNOWN CLEOPATRA Study Group

❮ Previous
Next ❯

Citations

Sep 30, 2020·Expert Opinion on Therapeutic Patents·Li LiXiao-Li Xu
May 15, 2020·Acta Pharmacologica Sinica·Xiang-Ling ChenLi-Guang Lou
May 13, 2020·Biomolecules·Karina Juarez-NavarroAngelica Lopez-Rodriguez
Sep 25, 2020·Signal Transduction and Targeted Therapy·Haiying LuJianyou Shi
Sep 2, 2020·European Journal of Medicinal Chemistry·Yuran QiuShaoyong Lu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis